SGX Pharmaceuticals, Inc. Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results

SAN DIEGO, March 4 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals will announce financial results for the fourth quarter and full year 2007 on Wednesday, March 12, 2008. The announcement will be followed by a live conference call and webcast at 8:00 a.m. Pacific Time. Mike Grey, President and Chief Executive Officer, and Todd Myers, Chief Financial Officer, will host the conference call to discuss financial results and business highlights.

Interested participants and investors may access the teleconference call by dialing 800-573-4752 (U.S./Canada) or 617-224-4324 (international), participant code 20358556. A telephonic replay will be available for seven days following the call. Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international), participant code 55640708.

A live webcast will be available under the investor relations section of the Company’s website at http://www.sgxpharma.com. Replays of the webcast will be available for 30 days following the event. Please connect to the Company’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About SGX Pharmaceuticals

SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The SGX oncology pipeline includes drug candidates from its FAST(TM) drug discovery platform, such as SGX523, a cMET kinase inhibitor currently in Phase 1 clinical studies, next generation BCR-ABL inhibitors being developed by SGX and in collaboration with Novartis, and JAK2 inhibitors. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company’s various filings with the Securities and Exchange Commission.

CONTACT: Bonnie Feldman, Sr. Director, Investor Relations of SGX
Pharmaceuticals, +1-858-344-8860

Web site: http://www.sgxpharma.com/

MORE ON THIS TOPIC